One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2 / CALR / MPL -mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10 9 /L) in 16%, leukocytosis (leukocytes >11 × 10 9 /L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2 -mutated patients were older (median 62 years) and CALR -mutated and TN (53 years for both) younger ( p < 0.001). Female gender clustered with TN (76%) and JAK2 (67%) vs CALR (46%) mutations ( p < 0.001). ExT clustered with CALR (type-2 more than type-1), TN and MPL , and leukocytosis with JAK2 mutation ( p < 0.001). In multivariable analysis, risk factors for arterial thrombosis-free survival were age ≥60 years (HR 2.0; p < 0.001) and JAK2 mutation (HR 1.3; p = 0.02) with borderline significance for male gender ( p = 0.08) and cardiovascular risk factors ( p = 0.08); for venous thrombosis-free survival, JAK2 mutation (HR 1.9; p = 0.03) with borderline significance for venous thrombosis history ( p = 0.07); for overall survival, older age ( p < 0.001), male gender (HR 1.9; p < 0.001), absolute neutrophil count (ANC) ≥ 8 × 10 9 /L (HR 1.8; p = 0.01), absolute lymphocyte count (ALC) < 1.7 × 10 9 /L (HR 1.2; p = 0.03); for myelofibrosis-free survival, CALR mutation (HR 2.7; p < 0.001, particularly for CALR type 1/1-like, HR 3.3) and MPL mutation (HR 3.9; p = 0.001); for leukemia-free survival, older age ( p = 0.03). Cytoreductive therapy appeared to mitigate both venous (HR 0.3; p = 0.01) and arterial thrombosis (HR 4; p = 0.04); there was a trend for aspirin in preventing arterial thrombosis recurrence. The current study provides real-world observations in essential thrombocythemia, representing a valid source document for interpreting current literature and planning future studies.